Physician profile
Alex David
NPI 1437140373
$6,051.47
in general payments reported to CMS, 2019-2025
26 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $440 · 2021: $939 · 2022: $1,081 · 2023: $1,008 · 2024: $918 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.55 |
| Education | $135.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,026.84 | 2019-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $734.52 | 2019-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $517.06 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $435.56 | 2022-2025 | Filspari |
| Astrazeneca Pharmaceuticals Lp | $432.61 | 2019-2024 | Farxiga, Evusheld, Lokelma |
| Mallinckrodt Hospital Products INC. | $421.40 | 2021-2025 | Acthar |
| Vifor Pharma, INC. | $363.00 | 2019-2023 | Veltassa |
| Glaxosmithkline, LLC. | $329.46 | 2019-2024 | Benlysta |
| Novartis Pharmaceuticals Corporation | $293.16 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $215.37 | 2022-2024 | |
| Aurinia Pharma U.S., INC. | $202.41 | 2021-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $197.93 | 2019-2023 | Jynarque |
| Opko Pharmaceuticals, LLC | $160.39 | 2021-2025 | Rayaldee |
| Ani Pharmaceuticals, INC. | $133.59 | 2022-2023 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $126.56 | 2019-2025 | Vafseo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $109.58 | 2021-2022 | |
| Ardelyx, INC. | $72.89 | 2024-2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $68.46 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.80 | 2025 | Jardiance |
| Vantive US Healthcare LLC | $43.87 | 2025 | Renal - Pd |
| Allergan, INC. | $31.48 | 2020 | |
| Calliditas Therapeutics US INC. | $27.77 | 2023-2025 | Tarpeyo |
| Lilly USA, LLC | $17.96 | 2023 | Jardiance |
| Scpharmaceuticals INC. | $15.95 | 2025 | |
| Alnylam Pharmaceuticals INC. | $14.42 | 2021 | |
| Mallinckrodt Enterprises LLC | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.